The mainstays of traditional cancer therapy have been surgical excision, chemotherapy, and radiation therapy. Cutting edge developments in research and trials involve the development of specific or autologous cancer vaccines, anti-angiogenic factors to prevent vascularization and growth, and targeted treatment using tumor specific antibodies either to localize immune stimulating cytokines, enhance radiation therapy, or trigger tumor specific apoptosis. Confluent Surgical Inc. is looking at ways to use the old tried-and-true chemotherapeutic agents with new localization technology to create